Join
Live feed
·
PRReleasevia Quantisnow
Spyre Therapeutics Inc. logo

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

ByQuantisnow·Wall Street's wire, on your screen.
SYRE· Spyre Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SYRE (Spyre Therapeutics Inc.) and more on Quantisnow.